contributors

uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy

Timur Mekhantev — Thu, 18 Jun 2026 22:27:26 +0000

Shares of uniQure N.V. (NASDAQ:QURE) pumped around 78% on Wednesday after the FDA cleared the path for a uniQure AMT-130 FDA approval filing under the accelerated pathway — a dramatic reversal from the agency’s prior stance that had sent the stock to a 52-week low of $8.73.

What Happened: The AMT-130 FDA Approval Path Opens

During a recent Type B meeting with the FDA, regulators communicated that the 3-year analysis from uniQure's Phase I/II clinical study of AMT-130 is acceptable as the primary basis for a Biologics License Application under the accelerated approval pathway. The company intends to submit the BLA in the third quarter of 2026.

These are the same AMT-130 data that were previously concluded as insufficient to support a marketing application. That shock had sent QURE shares to a 52-week low of $8.73. Wednesday's announcement means the regulatory overhang that has haunted the stock for months has been fully lifted.

The FDA also asked to finalize the design of the required confirmatory study before the BLA is filed, including the potential use of concurrent controls on standard-of-care therapy instead of a sham procedure — a notable shift in trial expectations for this rare neurodegenerative disorder.

"Today's announcement reflects the outcome we have worked toward throughout our continued regulatory engagement with FDA, and we are deeply grateful for FDA's genuine commitment to addressing the unmet need of Americans living with Huntington's disease".
— Matt Kapusta, ...

contributors

uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy

What Happened: The AMT-130 FDA Approval Path Opens

SpaceX Had The Best IPO In History—Now Comes The Hard Part

The Week in Plain Numbers

What the Cursor Deal Actually Tells You

Holding SpaceX Since The IPO? Why I'd Use The Strength To Sell

There is No Surprise with the Price Action

SpaceX IPO Lockup Calendar: What Most Investors Miss

What History Says About SpaceX IPO Lockup Expirations

SOXL ETF Rises Nearly 4% After Key Trading Signal

RWA.xyz's Bryan Choe: "People Still Confuse Tokenization With Liquidity"

On-Chain Capital Markets Are Still in Their Infrastructure Phase

The Rise of Exposure Without Ownership

Miduoduo Files For Hong Kong Listing; TikTok Tie-up, Southeast Asia Focus May Boost IPO prospects

Key Takeaways:

From Scarcity To Execution: China's AI Valuation Reset

Visual China Files For Hong Kong IPO As It Reframes For An AI Era

Key Takeaways:

Hyperliquid, Aster, And The Hard Truth About Decentralized Exchanges In The US

Intel's Next Move Could Be Bigger Than Today's Pop

Why Apple changes the conversation

The Taiwan risk trade

Nebius Shares Rise Over 5% After Key Trading Signal

Maybe It's Time To Rethink How The S&P 500 Is constructed

Changes in methodology don't have to mean big changes to performance ⚖️

Why Wall Street Is Turning Bullish On Rackspace Stock After Its AI Pivot

AMD Deal Gives Rackspace a Big AI Opportunity

Rackspace Is Cutting Costs to Invest in AI

UK Inflation Holds At 2.8% As Iran War Disrupts Energy Markets Ahead of BoE Decision

US-Iran Deal May Ease Price Strain

Fed Holds Rates Steady; Retail Sales Remain Resilient

Positioning